步科股份2020年11月12日在上交所科创板上市，发行数量为2100万股，发行价格为20.34元/股，保荐机 构为海通证券股份有限公司(更名：国泰海通证券股份有限公司)，保荐代表人为郑乾国、秦国亮。 步科股份募集资金总额为4.27亿元，扣除发行费用后，募集资金净额为3.81亿元。步科股份最终募集资 金净额较原计划多1.11亿元。步科股份发布的招股说明书显示，公司拟募集资金2.71亿元，其中9215万 元用于生产中心升级改造项目，8567万元用于研发中心升级建设项目，2503.70万元用于智能制造营销 服务中心建设项目，6800万元用于补充流动资金。 步科股份本次上市发行费用为4568.59万元，其中保荐机构国泰海通获得保荐与承销费用2715.75万元， 天健会计师事务所(特殊普通合伙)获得审计及验资费用800万元，国浩律师(深圳)事务所获得律师费用 556.60万元。 此外，步科股份8月2日披露公告显示，根据中国证券监督管理委员会于2025年5月16日出具的《关于同 意上海步科自动化股份有限公司向特定对象发行股票注册的批复》(证监许可〔2025〕1045号)，同意公 司2023年度向特定对象发行A股股票(以下 ...

Group 1 - The stock price of Jin'an Guoji remained stable at 11.84 yuan as of the close on August 4, 2025, with a trading volume of 161,405 hands and a transaction amount of 190 million yuan, resulting in a turnover rate of 2.23% [1] - The company has a total market capitalization of 8.62 billion yuan and a price-to-earnings ratio of 92.23 times [1] - Jin'an Guoji primarily engages in the manufacturing of electronic components, which accounts for 92.63% of its revenue, and also involves medical device manufacturing [1] Group 2 - On August 3, the company announced that independent director Yang Deli plans to reduce his holdings by no more than 5,000 shares within three months after a 15-trading-day period from the announcement date, currently holding 20,000 shares, representing 0.0027% of the total share capital [1] - On August 4, there was a net outflow of 25.69 million yuan in main funds, accounting for 0.3% of the circulating market value, with a cumulative net outflow of 140 million yuan over the past five trading days, representing 1.63% of the circulating market value [1]

容大感光2025年1月13日披露的以简易程序向特定对象发行股票并在创业板上市上市公告书显示，截至2025年1月7 日止，容大感光已向4个认购对象发行人民币普通股股票9,047,089股，募集资金总额人民币243,999,990.33元，扣 除与发行有关的费用人民币6,735,849.06元(不含税)，容大感光实际募集资金净额为人民币237,264,141.27元。本次 发行价格为26.97元/股。本次定增的保荐机构(主承销商)是华泰联合证券有限责任公司，保荐代表人是肖耿豪、阚 傲。 2023年，容大感光向特定对象发行股票募集资金。经中国证券监督管理委员会《关于同意深圳市容大感光科技股 份有限公司向特定对象发行股票注册的批复》(证监许可〔2023〕523号)同意，公司向特定对象发行人民币普通股 (A股)11,010,184股，面值为每股人民币1元，每股发行价格为人民币36.33元，本次募集资金总额为人民币 399,999,984.72元，扣除发行费用(不含税)人民币9,962,264.15元，实际募集资金净额为人民币390,037,720.57元。上 述募集资金到账情况已经立信会计师事务所(特殊普通合伙)审验， ...

德生科技7月30日股价报10.75元，较前一交易日下跌3.41%。当日开盘价为11.05元，最高触及11.08元， 最低下探至10.72元，成交量为21.23万手，成交额2.31亿元。 德生科技属于软件开发行业，主营业务为社保卡的生产、销售及信息化服务，主要产品包括一卡通及 AIOT应用、人社运营及大数据服务等。 7月30日晚间，德生科技公告称，控股股东、实际控制人虢晓彬计划减持不超过1284.86万股，占公司总 股本的3%，减持原因为个人资金需求及降低负债比例。按当前股价计算，预计套现约1.4亿元。此外， 公司2024年净利润同比下降72.13%，2025年一季度营收同比下滑12.75%。 7月30日，德生科技主力资金净流出3341.76万元。 风险提示：股市有风险，投资需谨慎。 ...

【环球网财经综合报道】据路透社等外媒报道，威瑞信公司（VeriSign）发布公告称，巴菲特旗下公司伯克希尔·哈撒韦（Berkshire Hathaway）将通过包销方 式二次发售430万股威瑞信普通股，每股定价285.00美元。此次交易预计将为伯克希尔带来约12.3亿美元现金收入，使其持股比例从14.2%降至9.6%。交易预 计于2025年7月30日完成，伯克希尔还可能额外出售51.5032万股以满足市场需求，威瑞信不会从中获得收益。 值得注意的是，伯克希尔最初于2012年四季度开始投资威瑞信，多年来持股比例保持相对稳定。此次减持旨在将持股比例降至10%以下，以避免触发监管义 务。285美元的发行价较威瑞信周一收盘价305.98美元折价6.9%。 截至3月底，伯克希尔现金储备达到创纪录的3477亿美元，并将于本周公布第二季度业绩时更新这一数据。 据悉，威瑞信是全球领先的互联网基础设施和域名注册公司，成立于1995年，总部位于弗吉尼亚州雷斯顿。公司主要提供域名注册和网络安全基础设施服 务，控制着".com"、".net"、".cc"和".name"等关键域名的注册业务。 监管文件显示，此次出售前伯克希尔持有超过 ...

Group 1 - The core point of the article highlights that Huaye Spice's stock price decreased by 2.05% on July 29, closing at 29.59 yuan, with a trading volume of 31,020 hands and a transaction amount of 0.92 billion yuan [1] - The company specializes in the research, development, production, and sales of spice products, which are widely used in the food and daily chemical industries [1] - In the first quarter of 2025, the company achieved an operating income of 97.79 million yuan and a net profit of 11.45 million yuan [1] Group 2 - On the evening of July 29, the company announced that its controlling shareholder and actual controller, Hua Wenliang, plans to reduce his holdings by no more than 2.24 million shares, accounting for 3% of the company's total share capital within the next three months [1] - The reason for the reduction is to repay debts and for personal financial arrangements, with the reduction methods including centralized bidding and block trading [1]

美国证券交易委员会（SEC）披露的144文件显示， 英伟达CEO黄仁勋拟再减持7.5万股公司股票。据了 解，英伟达CEO黄仁勋于7月11日、14日、15日连续三个交易日共减持22.5万股公司股票，价值约3800 万美元。这是其今年3月依据10b5-1规则披露的出售最多600万股股票计划的一部分。进入7月，英伟达 市值继续攀升，并突破4万亿美元，成为全球首家4万亿美元市值公司，截至当日美股收盘，英伟达市值 为4.18万亿美元。 ...

Group 1 - The core viewpoint of the article highlights NVIDIA's commitment to the Chinese market, as CEO Jensen Huang is set to attend a media briefing and the China International Supply Chain Promotion Expo on July 16 in Beijing, emphasizing the company's long-term dedication to China [1][2] - Jensen Huang has previously expressed the importance of the Chinese market during his visits to major cities, stating that NVIDIA has a deep cooperative relationship with China and plans to continue deepening this collaboration [1] - NVIDIA's market presence in China spans 25 years, with thousands of employees and numerous partnerships, indicating a strong foundation for future growth in the region [1] Group 2 - NVIDIA's market capitalization recently surpassed $4 trillion, while CEO Jensen Huang has sold approximately 225,000 shares valued at around $36.4 million as part of a pre-established stock sale plan allowing him to sell up to 6 million shares by the end of the year [2]

Core Viewpoint - The announcement reveals that the chairman and a major shareholder of Xianying Technology plan to reduce their holdings in the company due to personal funding needs, with a total potential reduction of up to 2,917,080 shares, representing 3% of the total share capital [1] Group 1: Shareholding and Reduction Plans - Chairman Xiao Jie holds 13,231,800 shares, accounting for 13.61% of the total share capital, while Nanjing Qiying holds 10,800,000 shares, representing 11.11% [2] - The planned reduction includes a maximum of 972,360 shares through centralized bidding and 1,944,720 shares through block trading, with adjustments based on any changes in the total share capital during the reduction period [1] Group 2: Financial Performance - Xianying Technology reported revenues of 687 million yuan, 682 million yuan, and 873 million yuan for the years 2022 to 2024, with net profits of 72.9 million yuan, 20.7 million yuan, and 8.1 million yuan respectively [2] - In Q1 2025, the company achieved revenues of 167 million yuan, a year-on-year decrease of 3.40%, while net profit increased significantly by 689.47% to 4.97 million yuan [2] Group 3: Company Background - Xianying Technology was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on September 22, 2021, with an initial public offering of 13.51 million shares at a price of 47.58 yuan per share [3] - The total funds raised from the IPO amounted to 643 million yuan, with a net amount of 583 million yuan after deducting issuance costs, exceeding the original plan by 232 million yuan [4]

Group 1 - Gannee Pharmaceutical announced a share reduction plan involving major shareholders and executives [1][2] - Beijing Xute Hongda Technology Co., Ltd. and its concerted actor Gan Zhongru hold a combined 241,116,992 shares, representing 40.11% of the total share capital [1][2] - The share reduction plan includes a maximum of 3,399,518 shares to be sold by Xute Hongda, accounting for 0.57% of the total share capital [2] Group 2 - Gannee Pharmaceutical was listed on the Shanghai Stock Exchange on June 29, 2020, with an initial public offering (IPO) of 40.2 million shares at a price of 63.32 yuan per share [3] - The total funds raised from the IPO amounted to 2.545 billion yuan, with a net amount of 2.441 billion yuan after expenses [3] - The funds from the IPO were allocated for various projects, including marketing network construction and product registration in the U.S. [3] Group 3 - In 2023, Gannee Pharmaceutical raised funds through a targeted issuance of shares, issuing 28,508,550 shares at a price of 27.12 yuan each [4] - The total amount raised from this issuance was approximately 773.15 million yuan, with a net amount of about 759.73 million yuan after expenses [4] - The combined total funds raised from both the IPO and the targeted issuance is approximately 3.318 billion yuan [4]